Dynamic Advisor Solutions’s CRISPR Therapeutics CRSP Stock Holding History

Dynamic Advisor Solutions’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,292	Closed	-$207K	–	712
2022 Q1	$207K	Sell	3,292 -665	-17%	-$41.8K	0.01%	673
2021 Q4	$300K	Buy	3,957 +662	+20%	+$57.8K	0.02%	560
2021 Q3	$369K	Buy	3,295 +1,098	+50%	+$138K	0.03%	512
2021 Q2	$356K	Sell	2,197 -33	-1%	-$4.01K	0.03%	503
2021 Q1	$272K	Sell	2,230 -1,277	-36%	-$193K	0.03%	523
2020 Q4	$537K	Buy	3,507 +41	+1%	+$4.85K	0.05%	350
2020 Q3	$290K	Buy	3,466 +21	+0.6%	+$1.86K	0.03%	436
2020 Q2	$253K	Buy	+3,445	New	+$201K	0.03%	417

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Dynamic Advisor Solutions's CRSP Position: Q2 2022 in Review

Dynamic Advisor Solutions sold out of CRISPR Therapeutics (CRSP) in Q2 2022, closing a stake of 3,292 shares — an estimated $207K sold.

Dynamic Advisor Solutions first reported a position in CRSP in Q2 2020 and held it in 8 quarters. The position peaked at $537K in Q4 2020. 435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

Dynamic Advisor Solutions reported no remaining CRISPR Therapeutics position as of Q2 2022 after selling out during the quarter.
Dynamic Advisor Solutions sold 3,292 CRISPR Therapeutics shares in Q2 2022, an estimated $207K.
Dynamic Advisor Solutions first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 8 quarters.
Dynamic Advisor Solutions's CRISPR Therapeutics position peaked at $537K in Q4 2020.
435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on Dynamic Advisor Solutions's 13F filing for Q2 2022, filed 27 Jul 2022.